HERTFORDSHIRE, England and
BENGALURU, India, Nov. 28, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ,
TASE: MYL) today announced that the company has signed an agreement
with the Medicines Patent Pool (MPP) to expand access to chronic
hepatitis C medicines in developing countries. The agreement
licenses Mylan to produce and market a generic version of
Bristol-Myers Squibb's DAKLINZA™ (daclatasvir) Tablets, 30 mg and
60 mg, for distribution in 112 low and middle income countries.
Daclatasvir Tablets, 30 mg and 60 mg, are indicated for use with
sofosbuvir, with or without ribavirin, for the treatment of
patients with chronic hepatitis C virus (HCV) genotype 1 or
genotype 3 infection in the U.S. and genotype 1, 3 and 4 in
Europe. The license allows Mylan
to develop fixed-dose combinations that offer the potential to
treat all of the six major genotypes of HCV. Earlier this year, the
World Health Organization added several new hepatitis C treatments,
including daclatasvir, to its essential medicines list,
highlighting the urgent need to promote equitable access to
innovative medicines1.
Commenting on today's announcement, Mylan President Rajiv Malik said, "We're committed at Mylan to
reducing the burden of hepatitis C on communities around the world
by providing access to high quality medicines that treat the
disease. We are pleased to work together with the MPP and
Bristol-Myers Squibb to help make daclatasvir available to low and
middle income countries at affordable prices."
Globally, 130 to 150 million people have chronic hepatitis C
infection2 and the vast majority live in low and middle
income countries3.
Forward-Looking Statements
This press release includes statements that constitute
"forward-looking statements," including with regard to future plans
and product offerings. These statements are made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Because such statements inherently
involve risks and uncertainties, actual future results may differ
materially from those expressed or implied by such forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to: any changes in or
difficulties with Mylan's or its partners' ability to develop,
manufacture, and commercialize products; any regulatory, legal, or
other impediments to Mylan's or its partners' ability to bring
products to market; Mylan's and its partners' ability to protect
intellectual property and preserve intellectual property rights;
the effect of any changes in Mylan's or its partners' customer and
supplier relationships and customer purchasing patterns; other
changes in third-party relationships; the impact of competition;
changes in the economic and financial conditions of the businesses
of Mylan or its partners; the scope, timing, and outcome of any
ongoing legal proceedings and the impact of any such proceedings on
Mylan's or its partners' business; actions and decisions of
healthcare and pharmaceutical regulators, and changes in healthcare
and pharmaceutical laws and regulations, in the United States and abroad; risks associated
with international operations; other uncertainties and matters
beyond the control of management; and the other risks detailed in
Mylan's filings with the Securities and Exchange Commission. Mylan
undertakes no obligation to update these statements for revisions
or changes after the date of this release.
About Mylan
Mylan is a global pharmaceutical company committed to setting
new standards in healthcare. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of more than 2,700 generic and branded pharmaceuticals,
including antiretroviral therapies on which nearly 50% of people
being treated for HIV/AIDS worldwide depend. We market our products
in more than 165 countries and territories. Our global R&D and
manufacturing platform includes more than 50 facilities, and we are
one of the world's largest producers of active pharmaceutical
ingredients. Every member of our more than 40,000 strong workforce
is dedicated to creating better health for a better world, one
person at a time. Learn more at mylan.com
1.
http://www.who.int/mediacentre/news/releases/2015/new-essential-medicines-list/en/
2.
http://www.who.int/mediacentre/factsheets/fs164/en/
3. Global epidemiology and genotype distribution of the
hepatitis C virus infection, Gower, Erin et al., Journal of
Hepatology , Volume 61 , Issue 1 , S45 - S57
Logo - http://photos.prnewswire.com/prnh/20140423/77793
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mylan-signs-sub-license-agreement-with-the-medicines-patent-pool-to-increase-access-to-hepatitis-c-treatment-in-developing-countries-300368162.html
SOURCE Mylan N.V.